Weight Loss Drugs Linked to Rare Eye Condition

Recent analyses of extensive adverse event data from 2017 to 2024 have highlighted a potential association between semaglutide-based drugs, such as Wegovy, and a rare optic nerve condition known as Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). This condition, sometimes called an eye stroke, involves sudden disruption of blood supply to the optic nerve, leading to rapid and often irreversible vision damage.

A study published in the British Journal of Ophthalmology in March 2026, utilizing over 30 million reports from the FDA Adverse Event Reporting System, identified a notable signal for Ischaemic Optic Neuropathy (ION) linked to GLP-1 receptor agonists. Notably, the findings suggested a higher risk associated with Wegovy compared to Ozempic, particularly in men.

Experts emphasize that while a link is being investigated, a confirmed cause-and-effect relationship has not been established. Potential contributing factors being examined include rapid metabolic changes, blood sugar fluctuations, dehydration, or vascular effects. However, common co-existing conditions like obesity, diabetes, and hypertension are also known risk factors for NAION, complicating direct attribution to the medication alone.

Patients are strongly advised against abruptly discontinuing their medication without consulting a healthcare professional. The overall risk is considered very low, and these drugs offer significant benefits for managing obesity and diabetes. However, any individual experiencing sudden blurred vision, visual field changes, or eye discomfort while on semaglutide treatment should seek immediate ophthalmological evaluation on the same day.